Objectives. To determine the effect of etanercept on endothelial dysfunction and on traditional cardiovascular (CV) risk factors in the adjuvant-induced arthritis (AIA) rat model.
Introduction
RA is the most common systemic autoimmune disease and is characterized by reduced life expectancy ranging between 3 and 18 years compared with the general population [1] . One of the leading causes of excess mortality in RA patients is cardiovascular (CV) disease due to accelerated atherogenesis, irrespective of classical CV risk factors [2] . Evidence from clinical studies shows that endothelial dysfunction (ED), the sine qua non condition for atherosclerosis appearance, is present in established RA [3] and is an important target for reducing CV diseases. Given that RA and atherosclerosis share common immunopathogenic features, it has been proposed that inflammatory mechanisms involved in the development of synovial lesions might contribute to ED [4] . This hypothesis is supported by in vivo experimental data showing that administration of the pro-inflammatory cytokine TNF-a depresses endothelium-dependent relaxation [5] . Surprisingly then, clinical studies on the effects of antiTNF-a on ED in RA have provided conflicting results. Some have shown improvement of endothelial function [69] , whereas some report no changes in ED despite efficient reduction of disease activity [1015] and others demonstrate only a transient improvement of ED [1618] .
The major difficulties in addressing whether or not antiTNF-a improves ED in clinical studies are that on the one hand, according to the international guidelines, TNF-a inhibitors are usually used in combination therapy with MTX, and on the other hand, RA patients take multiple medications, including CV drugs that can impact upon endothelial function. Thus, animal models of RA provide a unique opportunity to determine the impact of one given drug on endothelial function without the influence of other medications, with a direct assessment of vascular function of isolated vessels, and using rat cohorts with reproducible polyarthritis severity. Previous studies conducted on the widely used model of adjuvant-induced arthritis (AIA) in rats identified nitric oxide synthase (NOS) uncoupling, arginase-2 overactivation, endothelium-derived hyperpolarizing factor (EDHF) deficiency, cyclo-oxygenase-2 (COX-2) overactivity and overproduction of superoxide anions (O 2 ) as important pathomechanisms involved in ED [19] .
The aim of the present study was to investigate the effect of a curative treatment with etanercept on endothelial function in the AIA model in rats. Endothelial function was studied on isolated aortic rings on day 33 after arthritis induction (a time at which ED was previously characterized [20] ), and the mechanisms involved were dissected. The efficacy of etanercept on disease activity and joint damage was assessed by measurement of arthritic score and radiographic score, respectively. To assess whether the treatment modified CV risk factors, blood pressure, heart rate, glycaemia and lipid levels were also measured.
Methods

Animals
Six-week-old male Lewis rats (n = 60) were purchased from Janvier (Le Genest Saint Isle, France). Animals were kept under a 12:12 h light:dark cycle and allowed free access to food and water. The experimental procedures were approved by the local committee for ethics in animal experimentation no. 2012/001-CD of FrancheComté University (Besanç on, France) and complied with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (publication No. 85-23, revised 2011).
Induction and clinical evaluation of the arthritis model Adjuvant arthritis was induced by a single intradermal injection at the base of the tail of 120 ml of 1 mg of heatkilled Mycobacterium butyricum (Difco, Detroit, MI, USA) suspended in 0.1 ml of mineral oil [Freund's incomplete adjuvant (Difco, Detroit, MI, USA)]. The AIA model is characterized by rapid onset and progression of a robust and easily measurable polyarthritis (characterized by severe erythema and diffuse soft swelling with complete ankylosis and malformations in the paws), reduced locomotor activity, and is frequently associated with ear and tail inflammation, weight loss, anorexia and diarrhoea [21] . Rats were weighed and monitored for clinical signs of arthritis daily. The scoring system employed was as follows [22] : arthritis of one finger scored 0.1, weak and moderate arthritis of one big joint (ankle or wrist) scored 0.5, and intense arthritis of one big joint scored 1. Tarsus and ankle were considered as the same joint. The sum of the joint scores of the four limbs led to a maximum arthritis score of 6 for each rat.
Drug treatment
On the day of the first inflammatory symptoms (i.e. at day 1112 post-immunization), AIA rats were randomized into two groups. One group received etanercept, at 10 mg/kg (s.c.) every 3 days for 3 weeks (Etanercept, n = 30). The dose of etanercept was chosen on the basis of previous data on the AIA model that showed a significant reduction in arthritis severity and radiographic lesion [23] . The other group received saline at 1 ml/kg (s.c.) for 3 weeks (Vehicle, n = 30).
Tissue collection, blood pressure and heart rate measurements At 21 days after treatment initiation, rats were anaesthetized with pentobarbital (60 mg/kg, i.p.). Arterial systolic (SBP), diastolic (DBP), mean arterial blood pressure and heart rate were measured after cannulation of the left carotid artery and connection of the catheter to a pressure recorder system (Easy Graf, Gould, USA) under temperature control. Blood was withdrawn from the abdominal artery and centrifuged to obtain serum, divided into aliquots and stored at À80 C until analysis. The thoracic aorta was removed and immediately used for the group of rats used for vascular reactivity studies (n = 15/group) or frozen in liquid nitrogen and stored at À80 C until analysis for the group used for western blot (n = 15/group). Ankles were removed and placed in 4% formalin until assessment of radiographs.
Radiographical ex vivo analysis of joints of ankle and foot Radiographs of hind paws were performed with a Block Matching Algorithm High Resolution Digital X-ray system (40 mV, 10 mA)-D3A Medical Systems (Orleans, France). A score of 020 was determined for each paw using a www.rheumatology.oxfordjournals.org
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Etanercept and endothelial function in rat AIA grading scale modified from Ackerman et al. [24] . This score used the scale: 0 (normal); 1 (slight); 2 (mild); 3 (moderate); and 4 (severe) abnormalities in the tissue for each of five characteristic features of AIA. Radiographs take into account: (i) the soft tissue swelling; (ii) the osteoporosis as measured by bone density; (iii) the loss of cartilage shown by narrowing of the joint spaces; (iv) the bone erosions; and (v) the heterotopic ossification defined as proliferation of new bone tissue. The maximum score for each rat is 40.
Vascular reactivity
At the end of the treatment period, the thoracic aorta was excised, cleaned of connective tissue and cut into rings of $2 mm in length. The rings were suspended in Krebs solution (mol/l: NaCl 118, KCl 4.65, CaCl 2 2.5, KH 2 PO 4 1.18, NaHCO 3 24.9, MgSO 4 1.18, glucose 12, pH 7.4), maintained at 37 C and continuously aerated with 95% O 2 , 5% CO 2, for isometric tension recording in organ chambers, as previously described [25] . In some rings, the endothelium was mechanically removed. The completeness of endothelial denudation was confirmed by the absence of relaxation to the endothelium-dependent agonist acetylcholine (Ach, 10 À6 mol/l). After a 90-min equilibration period under a resting tension of 2 g, to determine whether etanercept improved endothelial function, rings with intact endothelium were constricted with phenylephrine (PE, 10 À6 mol/l), and endothelium-dependent relaxation to Ach (10 À11 to 10 À4 moles/l) was compared between the etanercept and the vehicle group. To investigate the contributions of NOS, tetrahydrobiopterin (the co-factor of NOS, BH 4 ), arginase, O 2 , COX-2 and EDHF, the rings were previously incubated for 1 h with the nonselective NOS inhibitor N W -nitro-L-arginine methyl ester (L-NAME, 10 À4 mol/l), BH4 (10 À7 mol/l), the arginase inhibitor N w -hydroxy-nor-L-arginine (nor-NOHA, 10 À4 mol/l), the superoxide dismutase mimetic Tempol (10 À4 mol/l), the selective COX-2 inhibitor (NS-398, 10 À5 mol/l) and the Ca 2+ -dependent K + channels inhibitors apamin (10 À7 mol/l) and charybdotoxin (10 À7 mol/l), respectively. Endothelium-denuded rings were used to determine the vasoconstrictive response to norepinephrine (NE, 10 À11 to 10 À4 mol/l) and the vasorelaxant response to the NOdonor sodium nitroprussiate (SNP, 10 À11 to 10 À4 mol/l) after pre-constriction with PE 10 À6 mol/l.
Western blots
To investigate whether the effects of etanercept on endothelial function relied on changes in protein expression, the protein content of endothelial nitic oxide synthase (eNOS) and Phospho-Ser1177-eNOS (P-eNOS, an activated form of eNOS at serine 1177 that produces a sustained release of endothelial NO), arginase-2, COX-2, p22 phox and p47 phox (membrane-bound and cytosolic components, respectively, of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a major vascular enzyme responsible for O 2 production in RA) [26] , were assessed in thoracic aortas from vehicle-treated and etanercept-treated AIA rats. After homogenization in ice-cold lysis buffer, thoracic aortas were sonicated and centrifuged (12 000 g, 20 min, +4 C) and the supernatants stored at À80 C until protein measurement by the Lowry method. Total proteins were separated by SDSPAGE on 12% (arginase-2, p22 phox or p47 phox ) or 8% (COX-2, P-eNOS and eNOS) SDSPAGE and transferred to polyvinyl difluoride (PVDF) membrane. After blocking unspecific binding with a 5% non-fat dry milk in Tris-buffered saline (TBS) buffer containing 0.1% Tween 20, membranes were incubated for 3 h at room temperature with anti-eNOS (mouse monoclonal 610297, BD Transduction Laboratories, 1/2500), antiP-eNOS (mouse monoclonal 612393, BD Transduction Laboratories, 1/1000), antiarginase-2 (rabbit polyclonal, Santa Cruz Biotechnology, 1/4000), antiCOX-2 (rabbit polyclonal aa 570598, Cayman Chemical, 1/2500), anti-p22 phox (mouse monoclonal sc-271968, Santa Cruz
Biotechnology, 1/4000), anti-p47 phox (mouse monoclonal sc-17845, Santa Cruz Biotechnology, 1/4000) or antib actin (mouse monoclonal, A5441, Sigma-Aldrich, 1/5000) antibodies and then for 2 h with a horseradish peroxidaseconjugated antimouse IgGs (for eNOS, P-eNOS, p22 phox , p47 phox and b-actin, 115-035-166 Jackson ImmunoResearch) or antirabbit IgGs (for arginase-2 and COX-2, 111-035-144 Jackson ImmunoResearch) and visualized using enhanced chemiluminescence (ECL+, GE Healthcare). The band densities were determined by scanning densitometry, and values were expressed as arbitrary units.
Blood measurements
Total cholesterol and triglycerides were measured in serum (Vista, Siemens, USA) and glucose was measured in blood by using a glycometer (GlucoMen, Menarini diagnostics, Italy).
Data and statistical analysis
Values are presented as means (S.E.M.). Data were analysed using GraphPad Prism software (ver. 5.0). Contractile responses to NE were expressed as the percentage of the maximum response to KCl 100 mmol/l. Relaxant responses to SNP and Ach were expressed as the percentage of relaxation of the contractile response to PE 10 À6 mol/l. Concentrationresponse curves to Ach, SNP and NE in vehicle-treated and etanercept-treated rats were compared by two-way analysis of variance for repeated measures. In each group (vehicle or etanercept), concentrationresponse curves to Ach with or without a specific inhibitor were compared by two-way analysis of variance for repeated measures. When necessary, to better understand the effect of inhibitors, the results were expressed as the area under the curve (AUC) (calculated from the individual concentrationresponse curves). Comparison between two values was assessed by an unpaired Student's t test, or a MannWhitney test when the data were not normally distributed. The relationship between two parameters was determined by linear regression analysis, and Spearman's correlation coefficient was calculated between these variables. P < 0.05 was considered statistically significant.
Results
Etanercept decreased clinical and radiological scores in AIA Etanercept did not influence body weights as compared with the vehicle (Table 1) . As expected, the treatment significantly decreased the mean arthritis scores (Fig.  1A) . The clinical effect of etanercept was associated with a slight but significant decrease in radiological score (Fig. 1B) . When detailing the different components of this score, it appeared that etanercept significantly reduced soft tissue swelling, loss of cartilage, and osteoporosis, but not bone erosion or new bone formation (supplementary Fig. S1 , available at Rheumatology Online).
Etanercept improved endothelial function in AIA To determine whether etanercept modified endothelial function, the concentrationresponse curves to Ach were compared between etanercept-and vehicle-treated AIA rats. As shown in Fig. 2A , anti-TNFa treatment significantly improved Ach-associated vasorelaxation. To ascertain that this effect was not due to impaired response of vascular smooth muscle cells to vasoconstrictive stimulus or to the relaxant effect of NO, the effect of etanercept on NE-induced vasoconstriction and on SNP-induced vasodilation was determined on endothelium-denuded aortic rings. Our results demonstrated that etanercept-treated rats displayed similar constriction to NE (Fig. 2B) as well as similar relaxation to the NO-donor SNP (Fig. 2C) . Of note, no correlation was found between the arthritis score and Ach-induced relaxation (AUC) (r = À0.322; P = 0.0817, all AIA rats, data not shown).
Etanercept improved the NOS/BH 4 /arginase balance in AIA NO is the key endothelial-derived relaxing factor in the macrovasculature. Its production by eNOS depends, in part, on the competition between eNOS and arginase for their common substrate: L-arginine [26] . Incubation of rings with L-NAME significantly blunted Ach-associated relaxation in both the vehicle (Fig. 3A) and the etanercept group (Fig. 3B) . However, the effect of L-NAME was greater in the etanercept group as compared with the vehicle group [% reduction of AUC: 87 (2) vs 77 (4) in vehicle, P = 0.042], indicating that NOS activity was enhanced by etanercept. This finding was confirmed by the higher expression of P-eNOS (the active form of eNOS) in the etanercept group (Fig. 3C ) associated with a higher total eNOS expression (Fig. 3D) . To assess the effect of treatment on arginase activity, aortic rings were incubated with nor-NOHA, an arginase inhibitor. In vehicle-treated rats 256 (14) 294 ( [27] . In the etanercept group, as a reflection of the normalization of arginase activity, nor-NOHA did not change the AUC of Ach-induced relaxation (Fig. 3F) . Consistent with this, aortic arginase-2 expression was significantly reduced by etanercept (Fig. 3G) . Additionally, since NOS activity also depends on the availability of its co-factor BH 4 , we investigated the impact of etanercept on BH 4 deficiency. As previously reported in this model [28] , incubation of aortic rings with BH 4 significantly improved Ach-induced relaxation in vehicle-treated AIA (Fig. 3H ). In contrast, BH 4 did not improve the response to Ach in etanercept-treated rats (Fig. 3I) . In summary, all the above indicated that the effect of etanercept on endothelial function was mediated by a modification of the NOS/BH 4 /arginase balance in favour of increased NOS activity/expression and reduced BH 4 deficiency, along with decreased arginase activity/ expression.
Etanercept blunted the COX-2 pathway but did not change EDHF production Besides NO, EDHF and COX-derived products are endothelium-derived relaxing factors with a relevant contribution to normal endothelial function. Previous data on the AIA model demonstrated that impaired vascular EDHF production and enhanced COX-2 activity are both contributors to ED [27] . To assess the contribution of EDHF in Ach-induced relaxation, rings were incubated with apamin/charybdotoxin, two K+ channel inhibitors. We previously demonstrated that incubation of aortic rings from aged-matched, control non-AIA Lewis rats with apamin/ charybdotoxin blunted the vasorelaxant response to Ach, as a reflection of the EDHF contribution to the relaxant effect of Ach in normal conditions [27] . In vehicle AIA, consistent with EDHF deficiency, apamin/charybdotoxin did not reduce, but actually slightly improved, Achinduced relaxation (Fig. 4A ). As shown in Fig. 4B , apamin/charybdotoxin did not change the response to Ach in etanercept-treated rats, thus indicating that etanercept did not improve EDHF production in AIA rats. As regards COX-2 activity, our results showed that NS-398, a COX-2 inhibitor, significantly improved Ach relaxation in the vehicle group (Fig. 4C) . Conversely, the COX-2 inhibitor did not change the Ach response in the etanercept group (Fig. 4D ), indicating that COX-2 activity was reduced by the treatment. Consistent with this, aortic COX-2 expression was significantly decreased by etanercept (Fig. 4E) . Altogether, these data demonstrated that etanercept did not change EDHF production, but reduced the deleterious contribution of COX-2 to ED.
Etanercept decreased superoxide anions production and NADPH oxidase expression
The role of excessive O 2 production and increased NADPH oxidase expression in AIA-associated ED has been previously demonstrated [28] . In the present study, the fact that the superoxide dismutase mimetic Tempol significantly improved Ach-induced vasodilation in the vehicle group confirmed this data (Fig. 5A) . In etanercepttreated AIA rats, Tempol did not change the response to Ach, thus indicating that the O 2 production decreased after treatment (Fig. 5B) . Western blot analysis of the components of NADPH oxidase showed that the beneficial effect of etanercept on O 2 -production relied, at least in part, on decreased expression of p22 phox (Fig. 5C ), but not of p47 phox (Fig. 5D ).
Effect of etanercept on CV risk factors
Data are presented in Table 1 . As compared with vehicle, etanercept induced a significant increase in SBP and heart rate (P < 0.05). Conversely, it did not change DBP, mean arterial blood pressure, blood glucose, total cholesterol or triglyceride levels.
Discussion
TNF-a is a pro-inflammatory cytokine secreted by activated macrophages and T cells and recognized by TNFa receptors that are expressed on critical cellular effectors Experiments were performed on thoracic aortic rings from vehicle-and etanercept-treated rats at the end of the treatment period (21 days after the onset of arthritis). Concentrationresponse curves of (A) Ach in endothelium-intact aortic rings preconstricted with PE 10 À6 mol/l and (B) NE on endothelium-denuded aortic rings; (C) SNP on endotheliumdenuded aortic rings preconstricted with PE 10 À6 mol/l. Values are the mean (S.E.M.) (n = 1015 aortic rings from 1015 rats per group). **P<0.01, by two-way ANOVA for repeated measures. Experiments were performed on thoracic aortic rings from vehicle-and etanercept-treated rats at the end of the treatment period (21 days after the onset of arthritis). Cumulative concentrationresponse curves of Ach were obtained after incubation or not with L-NAME at 10 À4 mol/l (A and B), with the NOS cofactor BH 4 at 10 À7 mol/l (H and I) or with the arginase inhibitor nor-NOHA at 10 À4 mol/l (E and F). Expression of eNOS (D), its phosphorylated form at Serine 1177, P-eNOS (C) and arginase-2 (G) were evaluated in aortas by western blotting. Values from the concentrationresponse curves are expressed as means (S.E.M.) (n = 915 rings from 915 rats per group), compared by two-way ANOVA for repeated measures. Values from immunoblots are the mean (S.E.M.) (n = 6 rats per group), compared by the MannWhitney test. *P < 0.05, ***P < 0.001.
www.rheumatology.oxfordjournals.org of vascular function/dysfunction, including vascular endothelial and smooth muscle cells [29] . This cytokine was previously reported to contribute to ED in animal models of low-grade inflammation such as fructose-induced hypertension [30] , ageing [31] , oestrogen deficiency [32] , chronic mild stress [33] and diabetes [34] , as evidenced by the improvement achieved by etanercept of Achinduced vasodilation in these models. A new finding provided by the present study is the positive impact of etanercept in ED associated with experimental arthritis, indicating that the cytokine also acts as a contributor to ED in situations associated with high-grade inflammation. This new data strongly suggests that lower CV events reported in RA patients treated with TNF-a inhibitors [35] are likely mediated by ED reduction and resonates with studies that show association between several polymorphisms of the TNF-gene and predisposition to CV complications in RA patients [36, 37] . An intriguing result Experiments were performed on thoracic aortic rings from vehicle-and etanercept-treated rats at the end of the treatment period (21 days after the onset of arthritis). Cumulative concentrationresponse curves of Ach were obtained after incubation or not with apamin/charybdotoxin at 10 À7 /10 À7 mol/l (A and B) or the COX-2 inhibitor NS-398 at 10 À4 mol/l (C and D). COX-2 expression (E) was evaluated in aortas by western blotting. Values from the concentrationresponse curves are the mean (S.E.M.) (n = 815 rings from 815 rats per group), compared by two-way ANOVA for repeated measures. Data from immunoblots are the mean (S.E.M.) (n = 6 rats per group), compared by the MannWhitney test. *P < 0.05. of our study was a lack of association between endothelial function and arthritis score in AIA rats. This data suggests that, even though TNF-a is likely involved in both vascular and joint detrimental processes in AIA, the pathomechanisms governing joint disease and vascular disease are probably distinct.
Classical CV risk factors, including hypertension, are minimally explaining the CV risk in RA [2, 38] . Besides, ED was reported to be present in RA patients independently of traditional risk factors [39] . Supporting this latter point are our results showing that etanercept did not modify triglycerides, total cholesterol or blood glucose levels, but resulted in a slight increase in SBP in AIA, as observed in RA patients [40, 41] . Hypertension is a littleknown side effect of antiTNF-a therapy in RA [42] , and the underlying mechanisms are still unknown. In our study, high SBP in etanercept AIA rats is likely the consequence of increased heart rate, since DBP was unaffected by the treatment. From a clinical perspective, all the above data indicate that the measurements of traditional CV risk factors such as blood pressure, lipid or glucose levels cannot be used as relevant end points to evaluate the effect of TNF-a inhibitors on endothelial function in RA.
The comprehensive analysis of the mechanisms underlying the effects of etanercept on endothelial function revealed both an improvement in NO production and a decrease in oxidative stress. This is consistent with studies showing an increased frequency of CV events and an increased risk of developing CV events in RA patients who carry eNOS [43] and methionine sulfoxide reductase gene polymorphisms [44] , an oxidative stressrelated enzyme. We showed that the improvement of endothelial NO production by etanercept was associated with an increase in eNOS phosphorylation at serine 1177 and in total eNOS expression, as previously reported in other animal models of ED [3034] . The new finding of the present study is that increased NO output by the endothelium is also consequent upon a decrease in arginase-2 expression/activity, an enzyme that starves eNOS of its substrate L-arginine, and that was previously reported to be upregulated in vitro by TNF-a [45] . Besides a switch of the eNOS/arginase balance towards the NOS pathway, etanercept also reduced oxidative stress and (more precisely) the production of O 2 , a radical oxygen species that contributes greatly to ED in AIA [19] . Our results suggest that reduced O 2 production by etanercept may involve several mechanisms. A major mechanism is likely a decrease in the expression of p22 phox , the membranebound subunit of NADPH oxidase. However, reduced arginase activity and the improvement of BH 4 availability may also be implicated. Indeed, under conditions of reduced substrate and/or cofactor availability, eNOS becomes uncoupled, that is, loses its ability to convert Larginine to L-citrulline, but removes an electron from www.rheumatology.oxfordjournals.org NADPH and donates it to molecular oxygen to yield O 2 instead of NO. An additional mechanism suggested by our study is a decrease in vascular COX-2 expression, since COX-2 is a source of oxygen radicals itself. Evidence that etanercept improves endothelial function through mechanisms other than increased NOS activity/expression might explain why the beneficial effects of DMARDs (including TNF-a inhibitors) on endothelial function were observed, despite unchanged plasma levels of dimethyl-Larginine, an endogenous inhibitor of eNOS [46, 47] .
In conclusion, despite the general consensus that the reduction of CV morbidity and mortality is of the utmost importance in RA, clinical data on the impact of TNF-a inhibitors on ED provided inconclusive results. This present study provides the first evidence of a favourable effect of etanercept on endothelial function in an animal model of RA, through pleiotropic effects on endothelial pathways, namely a switch of the eNOS/arginase balance towards the NOS pathway, a reduction of the NADPH oxidase/O 2 production pathway and a decrease in the COX-2 deleterious contribution. It is noteworthy that these pleiotropic effects of etanercept endorse the idea that etanercept interacts with a pivotal common endothelial effector (which is yet to be identified). The benefits of the TNF-a inhibitor on endothelial function occurred independently of its impact on CV risk factors. From a therapeutic point of view, this suggests that etanercept could be a good choice in RA patients at high risk of CV events. Further studies are warranted to determine whether the observed results are specific to etanercept or likely reflect a class effect of antiTNF-a agents.
